ICPT
Price:
$19
Market Cap:
$794.69M
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United State...[Read more]
Industry
Biotechnology
IPO Date
2012-10-11
Stock Exchange
NASDAQ
Ticker
ICPT
According to Intercept Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -12.41%. This represents a change of -36.73% compared to the average of -19.62% of the last 4 quarters.
The mean historical ROE of Intercept Pharmaceuticals, Inc. over the last ten years is -455.10%. The current -12.41% ROE has changed -97.27% with respect to the historical average. Over the past ten years (40 quarters), ICPT's ROE was at its highest in in the March 2020 quarter at 267.82%. The ROE was at its lowest in in the December 2017 quarter at -679.07%.
Average
-455.10%
Median
-102.47%
Minimum
-2199.24%
Maximum
194.32%
Discovering the peaks and valleys of Intercept Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.58%
Maximum Annual ROE = 194.32%
Minimum Annual Increase = -125.62%
Minimum Annual ROE = -2199.24%
Year | ROE | Change |
---|---|---|
2022 | 123.74% | 56.97% |
2021 | 78.83% | -59.43% |
2020 | 194.32% | -125.62% |
2019 | -758.50% | -53.08% |
2018 | -1616.53% | -26.50% |
2017 | -2199.24% | 1.58% |
2016 | -131.09% | 248.60% |
2015 | -37.60% | -69.34% |
2014 | -122.67% | 49.11% |
2013 | -82.27% | 24.24% |
The current ROE of Intercept Pharmaceuticals, Inc. (ICPT) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
132.30%
5-year avg
-395.63%
10-year avg
-455.10%
Intercept Pharmaceuticals, Inc.’s ROE is greater than Viking Therapeutics, Inc. (-12.73%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Akero Therapeutics, Inc. (-32.52%), less than Reata Pharmaceuticals, Inc. (47.21%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than TG Therapeutics, Inc. (-8.32%), greater than Hepion Pharmaceuticals, Inc. (-505.74%), less than PTC Therapeutics, Inc. (48.38%), less than Krystal Biotech, Inc. (6.34%), less than AVROBIO, Inc. (29.68%), greater than CohBar, Inc. (-58.44%), less than Ocean Biomedical, Inc. (75.64%), greater than Enveric Biosciences, Inc. (-201.01%), greater than Elevation Oncology, Inc. (-59.73%), less than Sarepta Therapeutics, Inc. (11.83%), greater than Mirati Therapeutics, Inc. (-40.45%),
Company | ROE | Market cap |
---|---|---|
-12.73% | $4.68B | |
-32.76% | $494.34M | |
-32.52% | $1.99B | |
47.21% | $6.57B | |
-71.78% | $6.81B | |
-8.32% | $5.01B | |
-505.74% | $3.46M | |
48.38% | $3.52B | |
6.34% | $4.59B | |
29.68% | $5.24M | |
-58.44% | $1.57M | |
75.64% | $20.89M | |
-201.01% | $3.23M | |
-59.73% | $33.10M | |
11.83% | $11.64B | |
-40.45% | $4.12B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Intercept Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Intercept Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Intercept Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Intercept Pharmaceuticals, Inc. (ICPT)?
What is the highest ROE for Intercept Pharmaceuticals, Inc. (ICPT)?
What is the 3-year average ROE for Intercept Pharmaceuticals, Inc. (ICPT)?
What is the 5-year average ROE for Intercept Pharmaceuticals, Inc. (ICPT)?
How does the current ROE for Intercept Pharmaceuticals, Inc. (ICPT) compare to its historical average?